Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Differences in renal hemodynamic effects of SGLT2 inhibitors between type 1 and type 2 diabetes are probably explained by patient characteristics such as baseline vascular resistance, age, diabetes duration, and concomitant ACE inhibitor/ARB or insulin use.
“The differential effects of SGLT2 inhibitors on renal hemodynamic physiology between patients with T1D and T2D are probably explained by differences in patient characteristics, including differences in baseline renal hemodynamic status, such as the degree of vascular resistance, age, diabetes duration, and concomitant medication use; in particular, ACE inhibitors or ARBs and insulin (van Bommel et”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as van Bommel et al., 2020
In a randomized double-blind trial in type 2 diabetes, dapagliflozin caused an acute GFR fall accompanied by reduced renal blood flow and renovascular resistance.
“In a randomized, double-blinded trial with dapagliflozin in patients with T2D, van Bommel et al. demonstrated that dapagliflozin causes an acute fall in GFR that was accompanied by a reduction in renal blood flow and renovascular resistance (van Bommel et al., 2020).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as van Bommel et al., 2020
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · see citing works
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · see citing works
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · see citing works
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887 · see citing works
Self-citationVallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483 · see citing works
Vallon, V., Mühlbauer, B., & Oßwald, H. (2006) · Physiological Reviews · doi:10.1152/physrev.00031.2005 · Cited by 450 · see citing works
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363 · see citing works
Self-citationKidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283 · see citing works
Self-citationSGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 220 · see citing works
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159 · see citing works
Self-citationRenal hemodynamic response to maximal vasodilating stimulus in healthy older subjects
Fuíano, G., Sund, S., Mazza, G., Rosa, M., Caglioti, A., Gallo, G., Natale, G., Andreucci, M., Memoli, B., Nicola, L. D., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590031052.x · Cited by 149 · see citing works
Impaired fasting glucose is associated with renal hyperfiltration in the general population
Melsom, T., Mathisen, U. D., Ingebretsen, O. C., Jenssen, T. G., Njølstad, I., Solbu, M. D., Toft, I., & Eriksen, B. O. (2011) · Diabetes Care · doi:10.2337/dc11-0235 · Cited by 134 · see citing works
SGLT inhibitor adjunct therapy in type 1 diabetes
McCrimmon, R. J., & Henry, R. R. (2018) · Diabetologia · doi:10.1007/s00125-018-4671-6 · Cited by 78 · see citing works
Urinary adenosine excretion in type 1 diabetes
Rajasekeran, H., Lytvyn, Y., Božović, A., Lovshin, J. A., Diamandis, E. P., Cattran, D. C., Husain, M., Perkins, B. A., Advani, A., Reich, H. N., et al. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00043.2017 · Cited by 56 · see citing works
Self-citationNørgaard, S. A., Briand, F., Sand, F. W., Galsgaard, E. D., Søndergaard, H., Sørensen, D. B., & Sulpice, T. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172537 · Cited by 48 · see citing works
Melsom, T., Nair, V., Schei, J., Mariani, L. H., Stefansson, V. T. N., Harder, J. L., Jenssen, T. G., Solbu, M. D., Norvik, J. V., Looker, H. C., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.11.011 · Cited by 46 · see citing works
Possible mechanism of efferent arteriole (Ef-Art) tubuloglomerular feedback
Ren, Y., Garvin, J. L., Liu, R., & Carretero, O. A. (2007) · Kidney International · doi:10.1038/sj.ki.5002161 · Cited by 44 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 694 · see citing works
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307 · see citing works
Schulze, P. C., Bogoviku, J., Westphal, J. G., Aftanski, P., Haertel, F., Grund, S., von Haehling, S., Schumacher, U., Möbius‐Winkler, S., & Busch, M. (2022) · Circulation · doi:10.1161/circulationaha.122.059038 · Cited by 226 · see citing works
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Sen, T., & Heerspink, H. J. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.016 · Cited by 161 · see citing works
Mechanisms of diabetic kidney disease and established and emerging treatments
Leon, V. M., Hilburg, R., & Suszták, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01171-3 · Cited by 101 · see citing works
Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
Martinez-Moreno, J. M., Fontecha‐Barriuso, M., Martín‐Sánchez, D., Guerrero‐Mauvecin, J., Gomá-Garcés, E., Fernández‐Fernández, B., Carriazo, S. M., Sánchez-Niño, M. D., Ramos, A. M., Ruiz‐Ortega, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114113 · Cited by 68 · see citing works
Miyata, K. N., Lo, C., Zhao, S., Liao, M.-C., Pang, Y., Chang, S., Peng, J., Kretzler, M., Filep, J. G., Ingelfinger, J. R., et al. (2021) · Clinical Science · doi:10.1042/cs20210094 · Cited by 67 · see citing works
We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury
Sridhar, V. S., Tuttle, K. R., & Cherney, D. Z. I. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.05.014 · Cited by 54 · see citing works
Self-citationCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 52 · see citing works
Self-citationSGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
Leoncini, G., Russo, E., Bussalino, E., Barnini, C., Viazzi, F. C., & Pontremoli, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094441 · Cited by 46 · see citing works
Koh, E. S., Kim, G., & Chung, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1764 · Cited by 42 · see citing works
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32 · see citing works
Relationship of Dapagliflozin With Serum Sodium
Yeoh, S. E., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.01.019 · Cited by 34 · see citing works
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 21 · see citing works
Self-citationScholtes, R. A., van Baar, M. J. B., Kok, M. D., Bjornstad, P., Cherney, D. Z. I., Joles, J. A., & van Raalte, D. H. (2020) · Nephrology · doi:10.1111/nep.13839 · Cited by 19 · see citing works
Self-citationThe Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Liu, J., Tian, J., Sodhi, K., & Shapiro, J. I. (2021) · The Journal of Membrane Biology · doi:10.1007/s00232-021-00192-z · Cited by 18 · see citing works
A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date
Tang, H., Xu, C., Zhang, P., Luo, T., Huang, Y., & Yang, X. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106415 · Cited by 17 · see citing works
Sridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 15 · see citing works
Self-citationRandomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.019 · Cited by 11 · see citing works
Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study
Zhao, S. S., Rajasundaram, S., Karhunen, V., Alam, U., & Gill, D. (2022) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2022.152058 · Cited by 10 · see citing works
van Ruiten, C. C., Hesp, A. C., & van Raalte, D. H. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.031 · Cited by 10 · see citing works
Jiménez, D. L., Sridhar, V. S., Mendoza, M. L., Scholtes, R. A., Schmieder, R. E., Cherney, D. Z. I., van Raalte, D. H., Prieto, F. J. T., Miramontes‐González, J. P., & van Bommel, E. J. M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae370 · Cited by 9 · see citing works
Self-citationKugathasan, L., Sridhar, V. S., Lovblom, L. E., Matta, S., Saliba, A., Debnath, S., Alakwaa, F., Nair, V., Bjornstad, P., Kretzler, M., et al. (2023) · Diabetes · doi:10.2337/db23-0694 · Cited by 9 · see citing works
Self-citationHadjadj, S., Cooper, M. E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., & Thomas, M. C. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100783 · Cited by 10 · see citing works
Song, J., Li, X., & Ni, J. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000534174 · Cited by 6 · see citing works
Li, X., Ge, J., & He, L. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5606697 · Cited by 5 · see citing works
RetractedSchumacher, C., Chorpash, A., Bolch, C., Eagan, K., Nimer, S., & Dril, E. V. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2902 · Cited by 5 · see citing works
Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact
Saulnier, P., & Bjornstad, P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104175 · Cited by 5 · see citing works
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
Oguz, F., Demoulin, N., Thissen, J. P., Jadoul, M. Y., & Morelle, J. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1966583 · Cited by 4 · see citing works
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
Gan, T., Song, Y., Guo, F., & Qin, G. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07758-7 · Cited by 4 · see citing works
Tjandrawinata, R. R., Harbuwono, D. S., Soegondo, S., Taslim, N. A., & Nurkolis, F. (2025) · Pharmaceuticals · doi:10.3390/ph18081101 · Cited by 3 · see citing works
Beldhuis, I. E., Martens, P., & ter Maaten, J. M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2659 · Cited by 3 · see citing works
Haidar, L., Crane, H. M., Nance, R. M., Doupe, M. B., Leong, C., Bamford, L. P., Burkholder, G., Cachay, E. R., Christopoulos, K., Commanday, A., et al. (2026) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003854 · Cited by 2 · see citing works
Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk
Odutayo, A., & Cherney, D. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00222024 · Cited by 1 · see citing works
Self-citationSahay, M., Prakash, S., Kataruka, M., Shah, H., Anthuvan, T., Gadia, S., Prasad, A., & Gupta, A. K. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_200_24 · Cited by 1 · see citing works
Role of Dapagliflozin versus Empagliflozin as add-on Therapy on Diabetic Nephropathy
Najim, H. D., Mohammed, M. M., & Rahmah, A. M. (2025) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.10.4.2410 · Cited by 1 · see citing works
Najim, H. D., Mohammed, M. M., & Rahmah, A. M. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v7i1(special).984 · Cited by 1 · see citing works
Kim, H., Won, H., Park, S., Lee, H., Cho, H., Kim, J. A., Jeong, N., Shin, H., Kim, Y., & Choi, N. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70015 · Cited by 1 · see citing works
Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen
Ganz, M. J., Bose, K., Herzog, C., Bender, S. T., Mertens, P. R., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01020-9
SGLT-2 inibitori nel trattamento dell’iponatremia. Quale ruolo?
Fibbi, B., & Norello, D. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01431-w
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · medRxiv · doi:10.1101/2024.05.28.24308079
Livelli di apelina e copeptina nei pazienti con SIAD cronica trattati con empagliflozin
Piombo, G., Guarnotta, V., & Arnaldi, G. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01587-z
Kugathasan, L., Ragi, N., Debnath, S., Sridhar, V. S., Maity, S., Feng, T., Treviño, E., Perkins, B. A., Cherney, D. Z. I., & Sharma, K. (2025) · Physiological Reports · doi:10.14814/phy2.70465 · Cited by 1 · see citing works
Self-citationMatsui, M., Kosugi, T., Kitamura, S., Nishimoto, M., Itano, A., Yamamoto, M., Yabuta, H., Oda, A., Kawakami, M., Tsushima, H., et al. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2624169
Fernandes, S., Hettinger, B., Ang, L., & Pop-Busui, R. (2026) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2026.04.007
Pan, J., Wang, X., Han, X., Cheng, H., Zhang, F., Chen, Y., Li, C., Wang, X., Cheng, Z., Zhang, Y., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01533-7
- Authors
- van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H.
- Affiliations
- University of Toronto (CA)
- Mount Sinai Hospital (CA)
- Boehringer Ingelheim (Canada) (CA)
- Boehringer Ingelheim (United States) (US)
- University Medical Center Utrecht (NL)
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 97
- Issue
- 4
- Pages
- 631-635
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3011798818
- Cited by
- 47
- References
- 19
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 5
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- AstraZeneca (BI 10773, NCT01392560)
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- SGLT2 inhibitors, renal hemodynamics, type 1 diabetes, type 2 diabetes, hyperfiltration, diabetic nephropathy, proximal tubule, glycosuria, plasma glucose, blood pressure, uric acid, body weight
- MeSH terms
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glucose, Hemodynamics, Humans, Kidney, Sodium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
